| Literature DB >> 29912873 |
Gregorio González-Alcaide1, Alejandro Salinas2, José M Ramos3,4.
Abstract
BACKGROUND: Chagas cardiomyopathy is a serious and common complication of Chagas disease.Entities:
Mesh:
Year: 2018 PMID: 29912873 PMCID: PMC6023249 DOI: 10.1371/journal.pntd.0006602
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Distribution of the document types by clinical interest, as assigned under the Chagas cardiomyopathy descriptor in MEDLINE.
| Document type | N | % |
|---|---|---|
| Case Reports | 188 | 9.7 |
| Clinical Trial | 49 | 2.5 |
| Evaluation Studies | 13 | 0.7 |
| Meta-Analysis | 5 | 0.3 |
| Observational Study | 4 | 0.2 |
| Practice Guideline | 3 | 0.1 |
| Validation Studies | 1 | 0.0 |
Fig 1Evolution of number of documents on Chagas cardiomyopathy in the MEDLINE database*.
*In the biennium 2015–2016, n = 76.
The 24 journals publishing the most reports on Chagas cardiomyopathy, their impact factor, subject category and ranking in the 2015 Journal Citation Reports; and their country and language of publication.
| Journal | No. art. | % | Accumulated % | Impact factor 2015 | Journal category (ranking) | Country | Language |
|---|---|---|---|---|---|---|---|
| 220 | 12.5 | 12.5 | 1.194 | Cardiac & cardiovascular systems (97/124) (Q4) | Brazil | Por | |
| 90 | 5.1 | 17.7 | 0.949 | Parasitology (29/36) (Q4) Tropical Medicine (12/19) (Q3) | Brazil | Eng | |
| 68 | 3.9 | 21.5 | 1.789 | Parasitology (18/36) (Q2)) Tropical Medicine (6/19) (Q2) | Brazil | Eng | |
| 64 | 4.6 | 25.2 | 4.638 | Cardiac & cardiovascular systems (20/124) (Q4) | Ireland | Eng | |
| 61 | 3.5 | 28.7 | 2.453 | Public, Environmental & Occupational Health (47/173) (Q2) Tropical Medicine (4/19) (Q1) | USA | Eng | |
| 42 | 2.4 | 31.0 | 0.589 | Medicine, General & Internal (116/155) (Q4) | Argentina | Spa | |
| 33 | 1.9 | 32.9 | 1.114 | Tropical Medicine (10/19) (Q2) | Brazil | Mul | |
| 31 | 1.8 | 34.7 | 3.949 | Parasitology (6/36) (Q1) Tropical Medicine (1/19) (Q1) | USA | Eng | |
| 31 | 1.8 | 36.5 | — | — | Mexico | Spa | |
| 28 | 1.6 | 38.1 | - | - | Brazil | Spa | |
| 26 | 1.5 | 39.5 | 4.332 | Cardiac & cardiovascular systems (26/124) (Q4) | USA | Eng | |
| 26 | 1.5 | 41.0 | 17.202 | Cardiac & cardiovascular systems (2/124) (Q4) Peripheral vascular disease (1/63) (Q1) | USA | Eng | |
| 24 | 1.4 | 42.4 | 1.631 | Public, Environmental & occupational Health (87/173) (Q3) Tropical Medicine (7/19) (Q2) | UK | Eng | |
| 21 | 1.2 | 43.6 | 0.955 | Medicine, General & Internal (95/155) (Q3) | Brazil | Eng | |
| 20 | 1.1 | 44.7 | 3.603 | Immunology (56/151) (Q2) Infectious Diseases (28/83) (Q1) | USA | Eng | |
| 19 | 1.1 | 45.8 | 1.440 | Cardiac & cardiovascular systems (88/124) (Q3) Engineering, Biomedical (47/76) (Q3) | USA | Eng | |
| 18 | 1.0 | 46.8 | 3.154 | Cardiac & cardiovascular systems (43/124) (Q4) | USA | Eng | |
| 17 | 1.0 | 47.8 | 2.291 | Immunology (102/151) (Q3) Infectious Diseases (46/83) (Q3) Microbiology (70/123) (Q3) | France | Eng | |
| 16 | 0.9 | 48.7 | 2.27 | Parasitology (15/36) (Q2) | Germany | Eng | |
| 16 | 0.9 | 49.6 | 0.40 | Medicine, General & Internal (1/155) (Q1) | Chile | Spa | |
| 16 | 0.9 | 50.5 | 2.380 | Parasitology (12/36) (Q2) Tropical Medicine (5/19) (Q2) | Netherlands | Eng | |
| 15 | 0.8 | 51.4 | 3.057 | Multidisciplinary Sciences (11/63) (Q1) | USA | Eng | |
| 15 | 0.8 | 52.2 | 4.596 | Cardiac & cardiovascular systems (22/124) (Q4) | Spanish | Spa | |
| 15 | 0.8 | 53.1 | 6.44 | Immunology (20/151) (Q1) Infectious Diseases (5/83) (Q1) Microbiology (14/123) (Q1) | USA | Eng |
Por: Portuguese; Eng: English; Spa: Spanish; Mul: Multi-language.
*Percentage of total records found in MEDLINE
†From 2001: Archivos de Cardiología de México, SCImago Journal Rank (SJR), Cardiology and Cardiovascular Medicine: 0.15 (255/340) (Q4).
‡SCImago Journal Rank (SJR), Medicine (miscellaneous): 0.545 (593/1826) (Q2).
Citation indicators of the most productive institutions on Chagas cardiomyopathy.
| Institution | N docs. | Total citations | Average citation per document ±SD | H Index |
|---|---|---|---|---|
| Universidade de São Paulo (Brazil) | 202 | 6297 | 31.17 (59.8) | 41 |
| Fundação Oswaldo Cruz (FIOCRUZ) (Brazil) | 146 | 3951 | 27.06 (34.9) | 34 |
| Universidade Federal de Minas Gerais (Brazil) | 118 | 2841 | 24.08 (26.2) | 31 |
| Universidade Federal do Rio de Janeiro (Brazil) | 44 | 1023 | 23.25 (25.3) | 19 |
| Universidad de los Andes (Venezuela) | 32 | 659 | 20.59 (22.8) | 15 |
| Universidad de Buenos Aires (Argentina) | 29 | 716 | 24.69 (29.5) | 14 |
| Albert Einstein College of Medicine (USA) | 29 | 581 | 20.03 (19.9) | 13 |
| Universidade Federal do Triângulo Mineiro (Brazil) | 26 | 793 | 30.50 (53) | 13 |
| Universidade Federal de Ouro Preto (Brazil) | 23 | 228 | 9.91 (8.9) | 10 |
| Universidade Federal de São Paulo (Brazil) | 23 | 378 | 16.43 (24.4) | 11 |
| Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (Argentina) | 23 | 697 | 30.30 (29.1) | 14 |
| Universidad de Chile (Chile) | 23 | 279 | 12.13 (16.5) | 9 |
| Universidad Nacional de Córdoba (Argentina) | 22 | 313 | 14.23 (12.3) | 11 |
| University of Texas Medical Branch (USA) | 20 | 502 | 25.10 (22.9) | 12 |
Distribution by country of Chagas cardiomyopathy records indexed in SCI-Expanded, and number and % of documents containing the MeSH descriptors “humans” and “animals”.
| Total docs | “Humans” | “Animals” | “Humans” and “animals” | Clinical | Epidemiological | Basic research | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | % | N | % | N | % | N | % | |
| Argentina | 173 | 16.2 | 74 | 42.8 | 40 | 23.1 | 59 | 34.1 | 47 | 27.2 | 18 | 10.4 | 108 | 62.4 |
| Australia | 1 | 0.1 | 1 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 100 |
| Belgium | 9 | 0.8 | 2 | 22.2 | 4 | 44.4 | 3 | 33.3 | 3 | 33.3 | 0 | 0 | 6 | 66.7 |
| Bolivia | 19 | 1.8 | 14 | 73.7 | 0 | 0 | 5 | 26.3 | 11 | 57.9 | 4 | 21 | 4 | 21 |
| Brazil | 568 | 53.1 | 314 | 55.3 | 138 | 24.3 | 116 | 20.4 | 214 | 37.7 | 56 | 9.9 | 298 | 52.5 |
| Canada | 17 | 1.6 | 12 | 70.6 | 3 | 17.6 | 2 | 11.8 | 7 | 41.2 | 3 | 17.6 | 7 | 41.2 |
| Chile | 28 | 2.6 | 19 | 67.9 | 1 | 3.6 | 8 | 28.6 | 11 | 39.3 | 11 | 39.3 | 6 | 21.4 |
| Colombia | 44 | 4.1 | 30 | 68.2 | 2 | 4.5 | 12 | 27.3 | 16 | 36.36 | 4 | 9.09 | 24 | 54.55 |
| Cuba | 1 | 0.1 | 1 | 100 | 0 | 0 | 0 | 0 | 1 | 100 | 0 | 0 | 0 | 0 |
| Czech Republic | 2 | 0.2 | 0 | 0 | 2 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 100 |
| Ecuador | 3 | 0.3 | 3 | 100 | 0 | 0 | 0 | 0 | 2 | 66.7 | 1 | 33.3 | 0 | 0 |
| El Salvador | 2 | 0.2 | 2 | 100 | 0 | 0 | 0 | 0 | 1 | 50 | 1 | 50 | 0 | 0 |
| Finland | 1 | 0.1 | 1 | 100 | 0 | 0 | 0 | 0 | 1 | 100 | 0 | 0 | 0 | 0 |
| France | 44 | 4.1 | 14 | 31.8 | 13 | 29.5 | 17 | 38.6 | 5 | 11.4 | 5 | 11.4 | 34 | 77.3 |
| Germany | 17 | 1.6 | 8 | 47.1 | 3 | 17.6 | 6 | 35.3 | 5 | 29.4 | 2 | 11.8 | 10 | 58.8 |
| Guatemala | 2 | 0.2 | 1 | 50 | 0 | 0 | 1 | 50 | 0 | 0 | 1 | 50 | 1 | 50 |
| Israel | 3 | 0.3 | 1 | 33.3 | 0 | 0 | 2 | 66.7 | 1 | 33.3 | 0 | 0 | 2 | 66.7 |
| Italy | 20 | 1.9 | 16 | 80 | 2 | 10 | 2 | 10 | 13 | 65 | 3 | 15 | 4 | 20 |
| Japan | 9 | 0.8 | 4 | 44.4 | 2 | 22.2 | 3 | 33.3 | 4 | 44.4 | 1 | 11.1 | 4 | 44.4 |
| Mexico | 27 | 2.5 | 8 | 29.6 | 5 | 18.5 | 14 | 51.9 | 6 | 22.2 | 8 | 29.6 | 13 | 48.1 |
| Netherlands | 1 | 0.1 | 1 | 100 | 0 | 0 | 0 | 0 | 1 | 100 | 0 | 0 | 0 | 0 |
| Norway | 1 | 0.1 | 1 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 100 |
| Panama | 1 | 0.1 | 1 | 100 | 0 | 0 | 0 | 0 | 1 | 100 | 0 | 0 | 0 | 0 |
| Paraguay | 3 | 0.3 | 0 | 0 | 2 | 66.7 | 1 | 33.3 | 0 | 0 | 1 | 33.3 | 2 | 66.7 |
| Peoples R China | 3 | 0.3 | 0 | 0 | 1 | 33.3 | 2 | 66.7 | 1 | 33.3 | 0 | 0 | 2 | 66.7 |
| Peru | 4 | 0.4 | 2 | 50 | 1 | 25 | 1 | 25 | 2 | 50 | 0 | 0 | 2 | 50 |
| Singapore | 1 | 0.1 | 0 | 0 | 1 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 100 |
| South Africa | 1 | 0.1 | 0 | 0 | 1 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 100 |
| Spain | 33 | 3.1 | 19 | 57.6 | 4 | 12.1 | 10 | 30.3 | 9 | 27.3 | 5 | 15.1 | 19 | 57.6 |
| Sweden | 1 | 0.1 | 0 | 0 | 0 | 0 | 1 | 100 | 0 | 0 | 0 | 0 | 1 | 100 |
| Switzerland | 10 | 0.9 | 3 | 30 | 2 | 20 | 5 | 50 | 4 | 40 | 4 | 40 | 2 | 20 |
| UK | 19 | 1.8 | 9 | 47.4 | 3 | 15.8 | 7 | 36.8 | 6 | 31.6 | 4 | 21 | 9 | 47.4 |
| Uruguay | 1 | 0.1 | 0 | 0 | 1 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 100 |
| USA | 275 | 25.7 | 108 | 39.3 | 93 | 33.8 | 74 | 26.9 | 75 | 27.3 | 32 | 11.6 | 168 | 61.1 |
| Venezuela | 77 | 7.2 | 44 | 57.1 | 9 | 11.7 | 24 | 31.2 | 31 | 40.3 | 8 | 10.4 | 38 | 49.3 |
*Percentage of total records.
† Percentage of total documents published in the country
Domestic and international collaboration on Chagas cardiomyopathy, records indexed in SCI-Expanded.
| Period | No. docs | Domestic collaboration | International collaboration | ||
|---|---|---|---|---|---|
| n | % | n | % | ||
| 1980–1989 | 136 | 65 | 47.8 | 26 | 19.1 |
| 1990–1999 | 208 | 112 | 53.8 | 53 | 25.5 |
| 2000–2009 | 405 | 293 | 72.3 | 95 | 23.4 |
| 2010–2016 | 320 | 266 | 83.1 | 104 | 32.5 |
| 1980–2016 | 1070 | 736 | 68.8 | 278 | 26.0 |
Analysis of collaboration and leadership at country level in research production on Chagas cardiomyopathy.
| Country | Total docs | % | No collaboration | % | Domestic collaboration | % | International collaboration | % | 1st position in documents in International collaboration | % | Corresponding (all documents) | % of total scientific production in the country |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Argentina | 173 | 16.2 | 110 | 63.6 | 93 | 53.8 | 63 | 36.4 | 30 | 47.6 | 118 | 68.2 |
| Australia | 1 | 0.1 | 1 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 100 |
| Belgium | 9 | 0.8 | 2 | 22.2 | 5 | 55.5 | 7 | 77.8 | 1 | 14.3 | 4 | 44.4 |
| Bolivia | 19 | 1.8 | 1 | 5.3 | 5 | 26.3 | 18 | 94.7 | 3 | 16.7 | 2 | 10.5 |
| Brazil | 568 | 53.1 | 399 | 70.2 | 376 | 66.2 | 169 | 29.7 | 101 | 59.8 | 442 | 77.8 |
| Canada | 17 | 1.6 | 0 | 0 | 2 | 11.8 | 17 | 100 | 6 | 35.3 | 6 | 35.3 |
| Chile | 28 | 2.6 | 22 | 78.6 | 17 | 60.7 | 6 | 21.4 | 2 | 33.3 | 21 | 75 |
| Colombia | 44 | 4.1 | 11 | 25 | 25 | 56.8 | 33 | 75 | 15 | 45.4 | 25 | 56.8 |
| Cuba | 1 | 0.1 | 1 | 100 | 1 | 100 | 0 | 0 | 0 | 0 | 1 | 100 |
| Czech Republic | 2 | 0.2 | 0 | 0 | 0 | 0 | 2 | 100 | 0 | 0 | 0 | 0 |
| Ecuador | 3 | 0.3 | 0 | 0 | 0 | 0 | 3 | 100 | 1 | 33.3 | 1 | 33.3 |
| El Salvador | 2 | 0.2 | 1 | 50 | 1 | 50 | 1 | 50 | 0 | 0 | 1 | 50 |
| Finland | 1 | 0.1 | 0 | 0 | 0 | 0 | 1 | 100 | 0 | 0 | 0 | 0 |
| France | 44 | 4.1 | 10 | 22.7 | 17 | 38.6 | 34 | 77.3 | 9 | 26.5 | 15 | 34.1 |
| Germany | 17 | 1.6 | 5 | 29.4 | 8 | 47.1 | 12 | 70.6 | 7 | 58.3 | 11 | 64.7 |
| Guatemala | 2 | 0.2 | 0 | 0 | 0 | 0 | 2 | 100 | 0 | 0 | 0 | 0 |
| Israel | 3 | 0.3 | 3 | 100 | 3 | 100 | 0 | 0 | 0 | 0 | 3 | 100 |
| Italy | 20 | 1.9 | 1 | 5 | 4 | 20 | 19 | 95 | 6 | 31.6 | 5 | 25 |
| Japan | 9 | 0.8 | 3 | 33.3 | 6 | 66.7 | 6 | 66.7 | 2 | 33.3 | 3 | 33.3 |
| Mexico | 27 | 2.5 | 14 | 51.8 | 12 | 44.4 | 13 | 48.1 | 6 | 46.1 | 15 | 55.6 |
| Netherlands | 1 | 0.1 | 0 | 0 | 0 | 0 | 1 | 100 | 0 | 0 | 0 | 0 |
| Norway | 1 | 0.1 | 0 | 0 | 1 | 100 | 1 | 100 | 0 | 0 | 0 | 0 |
| Panama | 1 | 0.1 | 1 | 100 | 1 | 100 | 0 | 0 | 0 | 0 | 1 | 100 |
| Paraguay | 3 | 0.3 | 0 | 0 | 2 | 66.7 | 3 | 100 | 0 | 0 | 0 | 0 |
| Peoples R China | 3 | 0.3 | 1 | 33.3 | 1 | 33.3 | 2 | 66.7 | 0 | 0 | 1 | 33.3 |
| Peru | 4 | 0.4 | 0 | 0 | 2 | 50 | 4 | 100 | 1 | 25 | 1 | 25 |
| Singapore | 1 | 0.1 | 1 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 100 |
| South Africa | 1 | 0.1 | 0 | 0 | 0 | 0 | 1 | 100 | 0 | 0 | 0 | 0 |
| Spain | 33 | 3.1 | 13 | 39.4 | 17 | 51.5 | 20 | 60.6 | 10 | 50 | 24 | 72.7 |
| Sweden | 1 | 0.1 | 1 | 100 | 1 | 100 | 0 | 0 | 0 | 0 | 0 | 0 |
| Switzerland | 10 | 0.9 | 5 | 50 | 3 | 30 | 5 | 50 | 0 | 0 | 3 | 30 |
| UK | 19 | 1.8 | 5 | 26.3 | 2 | 10.5 | 14 | 73.7 | 2 | 14.3 | 3 | 15.8 |
| Uruguay | 1 | 0.1 | 1 | 100 | 1 | 100 | 0 | 0 | 0 | 0 | 1 | 100 |
| United States | 275 | 25.7 | 125 | 45.4 | 158 | 57.4 | 150 | 54.5 | 66 | 44 | 162 | 58.9 |
| Venezuela | 77 | 7.2 | 55 | 71.4 | 42 | 54.5 | 22 | 28.6 | 10 | 45.4 | 43 | 55.8 |
Fig 2Collaboration network between countries on Chagas cardiomyopathy, records indexed in SCI-Expanded.
Fig 3Main research foci of the co-authorship network, generated from the documents on Chagas cardiomyopathy indexed in MEDLINE.
Most productive authors (>50 records) and authors with highest values of betweenness centrality in Chagas cardiomyopathy papers indexed in MEDLINE.
| Productivity | Betweenness centrality | ||||
|---|---|---|---|---|---|
| Rank | Author | N docs | Rank | Author | Value |
| 1 | Mady C | 65 | 1 | Marin-Neto JA | 0.086922 |
| 2 | Rocha MOC | 58 | 2 | Carvalho ACC | 0.064900 |
| 3 | Pileggi F | 57 | 3 | Ribeiro ALP | 0.061380 |
| 4 | Ianni BM | 53 | 4 | Higuchi ML | 0.049663 |
| 4 | Marin-Neto JA | 53 | 5 | Garg NJ | 0.041857 |
| 6 | Ribeiro ALP | 51 | 6 | Cunha-Neto E | 0.035044 |
| 7 | Tanowitz HB | 50 | 7 | Mady C | 0.034097 |
| 8 | Bellotti G | 48 | 8 | Xavier SS | 0.031581 |
| 9 | Bestetti RB | 47 | 9 | Teixeira MM | 0.029785 |
| 9 | Cunha-Neto E | 47 | 10 | Rassi A Jr | 0.029649 |
| 11 | Kalil J | 39 | 11 | Araujo-Jorge TC | 0.027069 |
| 12 | Bocchi EA | 38 | 12 | Sosa EA | 0.025525 |
| 13 | Rossi MA | 37 | 13 | Silva JS | 0.025439 |
| 14 | Stolf NAG | 36 | 14 | Guzman-Bracho C | 0.025424 |
| 15 | Higuchi ML | 35 | 15 | Chiale PA | 0.024764 |
| 16 | Carvalho ACC | 34 | 16 | Tanowitz HB | 0.024711 |
| 17 | Nunes MCP | 33 | 17 | Morillo CA | 0.023711 |
| 18 | Rassi A Jr | 32 | 18 | Sgammini H | 0.023431 |
| 19 | Teixeira MM | 30 | 19 | Rocha MOC | 0.023047 |
| 20 | Reyes PA | 29 | 20 | Ianni BM | 0.022476 |
| 21 | Andrade ZA | 27 | 21 | Elizari MV | 0.022334 |
| 22 | Andrade SG | 26 | 22 | Bocchi EA | 0.022315 |
| 22 | Carrasco HA | 26 | 23 | Paola AAV de | 0.022050 |
| 22 | dos Santos RR | 26 | 24 | Diez C | 0.021792 |
| 25 | Barretto ACP | 25 | 25 | Bestetti RB | 0.021572 |
| 25 | Davila DF | 25 | 26 | Grecco OT | 0.021507 |
| 25 | Jelicks LA | 25 | 27 | Correa-Oliveira R | 0.021383 |
| 25 | Maciel BC | 25 | 28 | Lopes ER | 0.021306 |
| 29 | Soares MBP | 24 | 29 | Dias JCP | 0.020487 |
| 30 | Weiss LM | 24 | 30 | Bottasso OA | 0.019793 |
Top 100 Medical Subject Headings (MeSH) from Chagas cardiomyopathy, records indexed in MEDLINE.
| MeSH | N docs | % | MeSH | N docs | % |
|---|---|---|---|---|---|
| Chagas Cardiomyopathy | 1755 | 100 | Prospective Studies | 57 | 3.2 |
| Humans | 1412 | 80.4 | Cytokines | 56 | 3.2 |
| Male | 986 | 56.2 | Disease Progression | 56 | 3.2 |
| Female | 867 | 49.4 | Polymerase Chain Reaction | 56 | 3.2 |
| Middle Aged | 740 | 42.2 | Biomarkers | 55 | 3.1 |
| Animals | 722 | 41.1 | Dogs | 53 | 3.0 |
| Adult | 697 | 39.7 | Young Adult | 52 | 3.0 |
| Trypanosoma cruzi | 576 | 32.8 | Heart Block | 49 | 2.8 |
| Chagas Disease | 444 | 25.3 | Cells, Cultured | 46 | 2.6 |
| Chronic Disease | 420 | 23.9 | Heart Conduction System | 46 | 2.6 |
| Electrocardiography | 341 | 19.4 | Age Factors | 45 | 2.6 |
| Aged | 339 | 19.3 | Hemodynamics | 45 | 2.6 |
| Myocardium | 324 | 18.5 | Tachycardia, Ventricular | 45 | 2.6 |
| Mice | 287 | 16.3 | Blood Pressure | 44 | 2.5 |
| Adolescent | 180 | 10.2 | Prevalence | 44 | 2.5 |
| Heart Failure | 168 | 9.6 | Child, Preschool | 42 | 2.4 |
| Heart | 165 | 9.4 | Cross-Sectional Studies | 42 | 2.4 |
| Disease Models, Animal | 146 | 8.3 | Fibrosis | 41 | 2.3 |
| Myocarditis | 136 | 7.7 | Severity of Illness Index | 41 | 2.3 |
| Antibodies, Protozoan | 124 | 7.1 | Exercise Test | 40 | 2.3 |
| Brazil | 121 | 6.9 | Recurrence | 40 | 2.3 |
| Arrhythmias, Cardiac | 115 | 6.5 | United States | 40 | 2.3 |
| Echocardiography | 114 | 6.5 | Bundle-Branch Block | 39 | 2.2 |
| Heart Ventricles | 106 | 6.0 | Myocytes, Cardiac | 39 | 2.2 |
| Acute Disease | 105 | 6.0 | Genetic Predisposition to Disease | 37 | 2.1 |
| Prognosis | 100 | 5.7 | Interferon-gamma | 37 | 2.1 |
| Heart Rate | 99 | 5.6 | Autonomic Nervous System | 36 | 2.0 |
| Rats | 99 | 5.6 | Genotype | 36 | 2.0 |
| Follow-Up Studies | 98 | 5.6 | Immunohistochemistry | 36 | 2.0 |
| Child | 95 | 5.4 | T-Lymphocytes | 36 | 2.0 |
| Cardiomyopathy, Dilated | 87 | 4.9 | Cardiomyopathies | 35 | 2.0 |
| Time Factors | 76 | 4.3 | Infant | 35 | 2.0 |
| Risk Factors | 75 | 4.3 | Magnetic Resonance Imaging | 35 | 2.0 |
| Case-Control Studies | 74 | 4.2 | Molecular Sequence Data | 35 | 2.0 |
| Myocardial Contraction | 73 | 4.1 | Survival Analysis | 35 | 2.0 |
| Trypanocidal Agents | 70 | 4.0 | Tumor Necrosis Factor-alpha | 35 | 2.0 |
| Parasitemia | 69 | 3.9 | CD8-Positive T-Lymphocytes | 34 | 1.9 |
| Antigens, Protozoan | 67 | 3.8 | Death, Sudden, Cardiac | 33 | 1.9 |
| Treatment Outcome | 67 | 3.8 | Inflammation | 33 | 1.8 |
| Ventricular Dysfunction, Left | 67 | 3.8 | Diagnosis, Differential | 32 | 1.8 |
| Heart Transplantation | 66 | 3.8 | Ventricular Function, Left | 32 | 1.8 |
| Mice, Inbred C57BL | 63 | 3.6 | Defibrillators, Implantable | 31 | 1.8 |
| Immunoglobulin G | 63 | 3.6 | DNA, Protozoan | 31 | 1.8 |
| Enzyme-Linked Immunosorbent Assay | 60 | 3.4 | Host-Parasite Interactions | 31 | 1.8 |
| Autoantibodies | 60 | 3.4 | Mice, Inbred C3H | 31 | 1.8 |
| Nitroimidazoles | 60 | 3.4 | Sensitivity and Specificity | 31 | 1.8 |
| Stroke Volume | 59 | 3.4 | Survival Rate | 31 | 1.8 |
| Aged, 80 and over | 58 | 3.3 | Autoimmunity | 30 | 1.7 |
| Mice, Inbred BALB C | 58 | 3.3 | Mexico | 30 | 1.7 |
| Retrospective Studies | 58 | 3.3 | Pacemaker, Artificial | 30 | 1.7 |
Fig 4Network of MeSH and their association with the research clusters.